Infant Bacterial Therapeutics AB Overview
Pro stress-test →Infant Bacterial Therapeutics AB is a clinical-stage Swedish pharmaceutical company developing novel therapeutics to prevent serious neonatal diseases in premature infants. The company focuses on probiotic-based drug candidates targeting conditions like necrotizing enterocolitis (NEC) and gastroschisis, addressing a critical unmet medical need in neonatal care.
Strategic Profile
Pro stress-test →IBT's lead candidate IBP-9414, a pharma-grade Lactobacillus reuteri probiotic strain, is in advanced clinical development with a pivotal Phase III trial (Connection Study) enrolling over 2,000 premature infants. The company has achieved FDA orphan drug designation for IBP-1016 in gastroschisis, positioning it for accelerated regulatory pathways and market exclusivity in rare pediatric indications.
Competitive Landscape
Pro stress-test →IBT operates in the specialized neonatal pharmaceutical space with limited direct competition for probiotic-based NEC prevention. Competitors include conventional probiotics and emerging biotechs targeting neonatal conditions, though few have advanced clinical programs. The company's orphan drug designation for gastroschisis provides competitive moat.
Industry Context
Infant Bacterial Therapeutics AB operates in Specialty Pharmaceutical / Neonatal Therapeutics.
Key facts
Founded: 2011 · Headquarters: Stockholm, Sweden · Employees: 10 · Market cap: $97.4M